ddp225
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2005 (NCT00230581)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Serotonin 3a (5-HT3a) receptorANTAGONIST
HTR3A antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ddp225
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00252993 | Phase 2 | Nov 1, 2005 | Dynogen Pharmaceuticals, Washington University in St. Louis |
| NCT00230581 | Phase 2 | Sep 1, 2005 | Dynogen Pharmaceuticals, University of Paris |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dynogen Pharmaceuticals | For profit | 2 | 2 | 1 | 2005 |
| University of Paris | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Washington University in St. Louis | Academic/Hospital | 1 | 0 | 1 | 2005 |
3 organizations
Page 1 / 1